Advertisement
Home 2018

Archives

Pediatricians are joining the call for action to prevent firearm deaths and injuries

AAP: Congress Urged to Act to Prevent Firearm Deaths

0
Following latest shooting, pediatricians join call for action to be taken to address firearm deaths, injury
Overall

CDC: No Change in Level of Uninsured in U.S. in 2017

0
Five percent of children uninsured in 2017, 41.3 and 55.0 percent had public and private coverage
The U.S. Preventive Services Task Force (USPSTF) concludes that the evidence is inadequate for primary care interventions to prevent maltreatment. These findings form the basis of a draft recommendation statement published online May 22 by the USPSTF.

Preventing Child Maltreatment Not Yet Feasible in Primary Care

0
USPSTF says evidence inadequate for primary care interventions to prevent child maltreatment
Aimovig (erenumab-aooe) has been approved by the U.S. Food and Drug Administration to prevent migraine headaches in adults.

FDA Approves Aimovig to Prevent Migraines

0
Patients taking Aimovig reported one to two fewer monthly migraine days than those taking pacebo
Doptelet (avatrombopag) has been approved by the U.S. Food and Drug Administration to treat adults with chronic liver disease who are slated to have a medical or dental procedure.

FDA OKs Doptelet for Liver Dz Patients Undergoing Procedures

0
Doptelet reduces the need for platelet transfusion or any rescue therapy on day of procedure
Lucemyra (lofexidine hydrochloride) has been approved by the U.S. Food and Drug Administration to treat symptoms of opioid withdrawal.

FDA Approves Non-Opioid Treatment for Opioid Withdrawal

0
Lucemyra is an oral selective alpha 2-adrenergic receptor agonist
Retacrit (epoetin alfa-epbx) has been approved by the U.S. Food and Drug Administration as the first "biosimilar" to the anemia drugs Epogen and Procrit.

FDA Approves ‘Biosimilar’ Drug to Treat Certain Types of Anemia

0
Retacrit is biosimilar to the drugs Epogen and Procrit
Diagnoses of major depression have increased since 2013

Rates of Major Depression Up Among U.S. Insured, Esp. Youth

0
Rate increased 33 percent from 2013 to 2016; rate increased faster among millennials, adolescents
The U.S. Food and Drug Administration has expanded its approval of the multiple sclerosis drug Gilenya (fingolimod) to include children aged 10 and older.

FDA Expands Use of MS Drug to Include Children

0
Gilenya is the first multiple sclerosis drug approved for children
The U.S. Food and Drug Administration has launched legal action to stop two stem cell clinics from providing unapproved treatments that have caused serious

FDA Targets Clinics Offering Unapproved Stem Cell Therapies

0
Clinics claim unapproved therapies can treat number of diseases and conditions, including ALS and cancer